These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29035083)

  • 1. Multiplicity-adjusted semiparametric benefiting subgroup identification in clinical trials.
    Schnell PM; Müller P; Tang Q; Carlin BP
    Clin Trials; 2018 Feb; 15(1):75-86. PubMed ID: 29035083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monte Carlo approaches to frequentist multiplicity-adjusted benefiting subgroup identification.
    Schnell PM
    Stat Methods Med Res; 2021 Apr; 30(4):1026-1041. PubMed ID: 33256562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian credible subgroups approach to identifying patient subgroups with positive treatment effects.
    Schnell PM; Tang Q; Offen WW; Carlin BP
    Biometrics; 2016 Dec; 72(4):1026-1036. PubMed ID: 27159131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian credible subgroup identification for treatment effectiveness in time-to-event data.
    Ngo D; Baumgartner R; Mt-Isa S; Feng D; Chen J; Schnell P
    PLoS One; 2020; 15(2):e0229336. PubMed ID: 32101562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subgroup analysis with semiparametric models toward precision medicine.
    Yuan A; Chen X; Zhou Y; Tan MT
    Stat Med; 2018 May; 37(11):1830-1845. PubMed ID: 29575056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subgroup identification for treatment selection in biomarker adaptive design.
    Lu TP; Chen JJ
    BMC Med Res Methodol; 2015 Dec; 15():105. PubMed ID: 26646831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlling the false-discovery rate when identifying the subgroup benefiting from treatment.
    Schnell PM
    Clin Trials; 2023 Aug; 20(4):394-404. PubMed ID: 37122134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations.
    Huber C; Benda N; Friede T
    Pharm Stat; 2019 Oct; 18(5):600-626. PubMed ID: 31270933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian approach to subgroup identification.
    Berger JO; Wang X; Shen L
    J Biopharm Stat; 2014; 24(1):110-29. PubMed ID: 24392981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of subgroups via partial linear regression modeling approach.
    Zhou Y; Yuan A; Tan MT
    Biom J; 2022 Mar; 64(3):506-522. PubMed ID: 34897799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new and unified method for regression analysis of interval-censored failure time data under semiparametric transformation models with missing covariates.
    Lou Y; Ma Y; Du M
    Stat Med; 2024 May; 43(11):2062-2082. PubMed ID: 38757695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
    Zhang Z; Chen R; Soon G; Zhang H
    Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient targeted learning of heterogeneous treatment effects for multiple subgroups.
    Wei W; Petersen M; van der Laan MJ; Zheng Z; Wu C; Wang J
    Biometrics; 2023 Sep; 79(3):1934-1946. PubMed ID: 36416173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semiparametric bayesian testing procedure for noninferiority trials with binary endpoints.
    Osman M; Ghosh SK
    J Biopharm Stat; 2011 Sep; 21(5):920-37. PubMed ID: 21830923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change plane model averaging for subgroup identification.
    Liu P; Li J; Kosorok MR
    Stat Methods Med Res; 2023 Apr; 32(4):773-788. PubMed ID: 36775991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semi-parametric Bayesian regression for subgroup analysis in clinical trials.
    Gamalo-Siebers M; Tiwari R
    J Biopharm Stat; 2019; 29(6):1024-1042. PubMed ID: 30747568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted design for adaptive clinical trials via semiparametric model.
    Zhang H; Yuan A; Tan MT
    Int J Biostat; 2020 Oct; 17(2):177-190. PubMed ID: 33027048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSICA: Decision trees for probabilistic subgroup identification with categorical treatments.
    Sysoev O; Bartoszek K; Ekström EC; Ekholm Selling K
    Stat Med; 2019 Sep; 38(22):4436-4452. PubMed ID: 31246349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.